942 related articles for article (PubMed ID: 20182618)
21. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
[TBL] [Abstract][Full Text] [Related]
23. p53 gain-of-function: tumor biology and bioinformatics come together.
Koonin EV; Rogozin IB; Glazko GV
Cell Cycle; 2005 May; 4(5):686-8. PubMed ID: 15846083
[TBL] [Abstract][Full Text] [Related]
24. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.
Vogiatzi F; Brandt DT; Schneikert J; Fuchs J; Grikscheit K; Wanzel M; Pavlakis E; Charles JP; Timofeev O; Nist A; Mernberger M; Kantelhardt EJ; Siebolts U; Bartel F; Jacob R; Rath A; Moll R; Grosse R; Stiewe T
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8433-E8442. PubMed ID: 27956623
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
27. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Terzian T; Suh YA; Iwakuma T; Post SM; Neumann M; Lang GA; Van Pelt CS; Lozano G
Genes Dev; 2008 May; 22(10):1337-44. PubMed ID: 18483220
[TBL] [Abstract][Full Text] [Related]
28. p53 mutations promote proteasomal activity.
Oren M; Kotler E
Nat Cell Biol; 2016 Jul; 18(8):833-5. PubMed ID: 27463250
[TBL] [Abstract][Full Text] [Related]
29. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
30. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53: one name, many proteins.
Freed-Pastor WA; Prives C
Genes Dev; 2012 Jun; 26(12):1268-86. PubMed ID: 22713868
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the biological activities of wild-type and mutant p53.
Zambetti GP; Levine AJ
FASEB J; 1993 Jul; 7(10):855-65. PubMed ID: 8344485
[TBL] [Abstract][Full Text] [Related]
33. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.
Gualberto A; Aldape K; Kozakiewicz K; Tlsty TD
Proc Natl Acad Sci U S A; 1998 Apr; 95(9):5166-71. PubMed ID: 9560247
[TBL] [Abstract][Full Text] [Related]
34. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
Monteith JA; Mellert H; Sammons MA; Kuswanto LA; Sykes SM; Resnick-Silverman L; Manfredi JJ; Berger SL; McMahon SB
Mol Oncol; 2016 Oct; 10(8):1207-20. PubMed ID: 27341992
[TBL] [Abstract][Full Text] [Related]
35. Crippling p53 activities via knock-in mutations in mouse models.
Iwakuma T; Lozano G
Oncogene; 2007 Apr; 26(15):2177-84. PubMed ID: 17401426
[TBL] [Abstract][Full Text] [Related]
36. An N
Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
[TBL] [Abstract][Full Text] [Related]
37. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in p53 research and cancer treatment.
Suzuki K; Matsubara H
J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
[TBL] [Abstract][Full Text] [Related]
39. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53: it's not all one and the same.
Kennedy MC; Lowe SW
Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
